Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GB-4362 With Enfortumab Vedotin and Pembrolizumab in Advanced Urothelial Cancer
NCT07484022Phase 1Recruiting
- Sponsor
- Generate Biomedicines
- Start
- Jun 2026
- Primary completion
- Jun 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of GB-4362 in urothelial carcinoma (UC), sponsored by Generate Biomedicines. Primary endpoint: Incidence of Adverse Events and Serious Adverse Events at 18 weeks. Started Jun 2026; status: recruiting.
02
Drugs
GB-4362
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT07484022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07484022.